Teva Pharmaceutical Industries Ltd Reports Positive Phase 2a Results for TEV‑408 in Celiac Disease
Teva Pharmaceutical Industries Ltd (TEVA.TA) announced that its investigational anti‑IL‑15 monoclonal antibody, TEV‑408, achieved its primary endpoint in a Phase 2a study involving adults with celiac disease. The study demonstrated a statistically significant and clinically meaningful reduction in gluten‑induced intestinal damage compared with placebo. The topline results were presented by the company on 2 September 2026 and were subsequently reported by multiple financial news outlets, including Finanznachrichten, Reuters, and FierceBiotech.
Study Details
- Population: Adults diagnosed with celiac disease.
- Design: Randomized, double‑blind, placebo‑controlled.
- Primary Endpoint: Prevention of gluten‑induced intestinal damage.
- Outcome: TEV‑408 met the primary endpoint, showing a statistically significant and clinically meaningful benefit over placebo.
The successful Phase 2a data support Teva’s strategy of developing “pipeline‑in‑a‑product” candidates, reinforcing the company’s focus on anti‑inflammatory therapies for autoimmune conditions.
Acquisition of BioXcel Assets
On 31 August 2026, Teva announced the acquisition of certain assets from BioXcel Therapeutics for up to US$125 million. The purchase expands Teva’s portfolio in biologic and cell‑based therapies, providing access to BioXcel’s pipeline and technology platforms. The transaction is expected to be completed within the next 12 months, subject to customary closing conditions.
Market Context: Biosimilars
A MarketsandMarkets report highlighted the rapid growth of the biosimilars market, projecting a value of USD 70.79 billion by 2036, up from USD 37.39 billion in 2026, at a compound annual growth rate of 6.6 %. Teva’s continued investment in biologics positions the company to capture a share of this expanding market.
Financial Snapshot (as of 31 August 2026)
| Metric | Value |
|---|---|
| Close Price | 11,020 ILA |
| 52‑Week High | 11,440 ILA |
| 52‑Week Low | 6,082 ILA |
| Market Capitalisation | 42,850,374,048.2 ILA |
| P/E Ratio | 60.14 |
Teva’s stock traded near its 52‑week high following the announcement of the Phase 2a results, reflecting investor confidence in the company’s therapeutic pipeline and recent asset acquisition.
The combined achievements in the celiac disease study and the strategic acquisition of BioXcel assets reinforce Teva’s commitment to expanding its biologic portfolio and advancing its anti‑inflammatory drug development program.
